Action Required: Password Reset on Next Login
As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.
To reset your password, please visit the Reset Password page.
We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Vividion Therapeutics Inc.
Headquarters: San Diego, CA, United States of America
Website: N/A
Year Founded: 2013
Status: Acquired
BioCentury | Jan 23, 2025
Management Tracks
New COOs for Vividion, Edgewise
Plus: Pacira names new heads of commercial, CBO and updates from Vib spinout Tanai, Arcus, Kyverna and Alx
BioCentury | May 22, 2024
Management Tracks
FDA vet Singh joining CRDO Precision for Medicine
Plus: de Moerlooze to depart Bavarian and updates from Engitix, Actio and Oruka
BioCentury | May 6, 2024
Product Development
Tale of two WRN inhibitors: a covalent and a non-covalent molecule enter the clinic
As the first two programs targeting the helicase WRN enter the clinic for MSI+ cancers, they set up a comparison of different inhibitory mechanisms
BioCentury | May 2, 2024
Deals
Novartis gains α-emitter, radioligand platform via $1B Mariana takeout
Largest upfront M&A payment for a preclinical biotech in three years
BioCentury | Feb 15, 2024
Emerging Company Profile
BridGene: a pairwise approach to chemoproteomics for hard targets
The California company’s IMTAC screening platform for hard-to-drug targets has found partners in Takeda and Galapagos
BioCentury | Oct 10, 2023
Emerging Company Profile
Hyku: tapping new targets by taking chemoproteomics beyond cysteine
In co-leading Hyku’s $56M seed round, RA Capital added to its portfolio of chemoproteomics companies
BioCentury | Sep 8, 2023
Management Tracks
CRISPR CEO Kulkarni named chair as Novak departs
Plus: updates from Vividion, Rapport, One Biosciences, enGene, Anokion and more
BioCentury | Mar 23, 2023
Management Tracks
Treco to succeed Bolte as CEO of Inozyme
Plus: Seagen’s Siegall to be CEO at Morphimmune and updates from Jasper, Vividion and more
BioCentury | Jan 4, 2023
Emerging Company Profile
Versant-backed Belharra: light-based chemoproteomics for all amino acids
Scripps spinout launches with $50M series A, $80M up front deal with Genentech to chase difficult targets
BioCentury | Oct 14, 2022
Emerging Company Profile
Matchpoint: a toolkit to create covalent therapies for immunology
Chemoproteomics, machine-learning start-up has $100M from investors including Atlas, Access Biotechnology and Sanofi Ventures
Items per page:
1 - 10 of 49